While no comprehensive data on secreted factors determined by KRAS or BRAF oncogenes are available in CRC, this might comprise a further molecular level of specificity determining both the distinct roles of KRAS and BRAF in tumor progression and therapy response. This evidence concerns the gene KRAS and colorectal carcinoma.